Oral anticoagulation therapy: An update on usage, costs and associated risks

Emmanuel J. Favaloro, Leonardo Pasalic, Giuseppe Lippi

Research output: Contribution to journalLetterpeer-review

Abstract

Oral anticoagulant therapy (OAT) is prescribed for various reasons,1e3 and now includes several agent classes.Vitamin K antagonists (VKAs), including warfarin, represent classical oral anticoagulants and remain commonly used for treatment of venous thromboembolism (VTE) [including deep vein thrombosis (DVT) and pulmonary embolism (PE)], stroke prophylaxis in atrial fibrillation (AF), and to reduce the risk of prosthetic heart valve thrombosis and thromboembolism. More recent availability of direct inhibitors of either thrombin (factor IIa) or activated factor X (FXa), have transformed the OAT landscape as representing ‘direct oral anticoagulants’ (or DOACs),sometimes referred to as ‘non Vitamin K antagonist oral anticoagulants’ (or NOACs). Here, we update the use, costs and some associated risks related to OAT.
Original languageEnglish
Pages (from-to)736-741
Number of pages6
JournalPathology
Volume52
Issue number6
Early online date01 Aug 2020
DOIs
Publication statusPublished - 01 Oct 2020

Fingerprint Dive into the research topics of 'Oral anticoagulation therapy: An update on usage, costs and associated risks'. Together they form a unique fingerprint.

Cite this